Pfizer and BioNTech Report Positive Results from COVID-19 Vaccine Trial

Pfizer and BioNTech have announced positive early results from a phase 1 /2 study of their lead COVID-19 vaccine candidate in the U.S.

All 24 volunteers who received either two 10 mcg or 30 mcg doses of the messenger RNA-based vaccine produced neutralizing antibodies up to 2.8 times more than those seen in recovered COVID-19 patients, and no serious adverse events were reported.

The companies expect to begin a phase 2b/3 trial of the vaccine later this month.